Vismodegib in the treatment of advanced BCC.
Copyright policy )Vismodegib in the treatment of advanced BCC.
Basal-cell carcinoma (BCC) is the most commonly diagnosed malignancy, comprising over 80%of non-melanoma skin cancers. Surgical excision is adequate treatment for most BCCâ s. Options are however limited for the minority of patients presenting with locally advanced inoperable or metastatic BCC. The Hedgehog signalling pathway is a critical driver in the pathogenesis of both sporadic and hereditary BCC. On 31st January 2012, based on a phase II clinical trial the US Food and Drug Administration approved Vismodegib (Erivedgefi, Roche) a first-in-class, small-molecule oral Hedgehog-inhibitor for the treatment of locally advanced inoperable and metastatic BCC. We present our experience treating the first Irish patient with this agent.
peer-review
No funding
Leinster
Compassionate Use Trials, Male, Skin Neoplasms, Pyridines, Antineoplastic Agents, Middle Aged, SKIN CANCER, Treatment Outcome, Humans, Anilides, Basal Cell Carcinoma
Compassionate Use Trials, Male, Skin Neoplasms, Pyridines, Antineoplastic Agents, Middle Aged, SKIN CANCER, Treatment Outcome, Humans, Anilides, Basal Cell Carcinoma
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!